{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:46:04Z","timestamp":1789541164934,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1208\/s12249-019-1291-5","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T18:03:49Z","timestamp":1548266629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol\u2013Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties"],"prefix":"10.1208","volume":"20","author":[{"given":"Chunxia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhuang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guocheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"1291_CR1","doi-asserted-by":"publisher","first-page":"1800328","DOI":"10.1183\/13993003.00328-2018","volume":"52","author":"E Polverino","year":"2018","unstructured":"Polverino E, Dimakou K, Hurst J, Angel Martinez-Garcia M, Miravitlles M, Paggiaro P, et al. The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions. Eur Respir J. 2018;52:1800328. \nhttps:\/\/doi.org\/10.1183\/13993003.00328-2018\n\n.","journal-title":"Eur Respir J"},{"key":"1291_CR2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/17476348.2018.1481392","volume":"12","author":"R Athanazio","year":"2018","unstructured":"Athanazio R, da Costa JC, de la Rosa Carrillo D, Martinez-Garcia MA. Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis. Expert Rev Respir Med. 2018;12:569\u201384.","journal-title":"Expert Rev Respir Med"},{"key":"1291_CR3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/17476348.2018.1500179","volume":"12","author":"R Amaro","year":"2018","unstructured":"Amaro R, Panagiotaraka M, Alcaraz V, Torres A. The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. Expert Rev Respir Med. 2018;12:683\u201391.","journal-title":"Expert Rev Respir Med"},{"key":"1291_CR4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","volume":"186","author":"JD Chalmers","year":"2012","unstructured":"Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Resp Crit Care. 2012;186:657\u201365.","journal-title":"Am J Resp Crit Care"},{"key":"1291_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","volume":"85","author":"Q Zhou","year":"2015","unstructured":"Zhou Q, Leung SSY, Tang P, Parumasivam T, Loh ZH, Chan H-K. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev. 2015;85:83\u201399.","journal-title":"Adv Drug Deliv Rev"},{"key":"1291_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","volume":"157","author":"F Ungaro","year":"2012","unstructured":"Ungaro F, d\u2019Angelo I, Coletta C, d\u2019Emmanuele di Villa Bianca R, Sorrentino R, Perfetto B, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release. 2012;157:149\u201359.","journal-title":"J Control Release"},{"key":"1291_CR7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","volume":"11","author":"BS Quon","year":"2014","unstructured":"Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11:425\u201334.","journal-title":"Ann Am Thorac Soc"},{"key":"1291_CR8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","volume":"2","author":"AF Barker","year":"2014","unstructured":"Barker AF, O\u2019Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738\u201349.","journal-title":"Lancet Respir Med"},{"key":"1291_CR9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1753465813487412","volume":"7","author":"JA Justo","year":"2013","unstructured":"Justo JA, Danziger LH, Gotfried MH. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2013;7:272\u201387.","journal-title":"Ther Adv Respir Dis"},{"key":"1291_CR10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/13543784.2017.1364728","volume":"26","author":"MK Cartlidge","year":"2017","unstructured":"Cartlidge MK, Hill AT. Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis. Expert Opin Investig Drugs. 2017;26:1091\u20137.","journal-title":"Expert Opin Investig Drugs"},{"key":"1291_CR11","doi-asserted-by":"publisher","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","volume":"51","author":"A De Soyza","year":"2018","unstructured":"De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702052. \nhttps:\/\/doi.org\/10.1183\/13993003.02052-2017\n\n.","journal-title":"Eur Respir J"},{"key":"1291_CR12","doi-asserted-by":"publisher","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","volume":"51","author":"T Aksamit","year":"2018","unstructured":"Aksamit T, De Soyza A, Bandel T-J, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702053. \nhttps:\/\/doi.org\/10.1183\/13993003.02053-2017\n\n.","journal-title":"Eur Respir J"},{"key":"1291_CR13","first-page":"29","volume":"30","author":"C Haworth","year":"2017","unstructured":"Haworth C, Wanner A, Froehlich J, O\u2019Neal T, Davis A, Gonda I, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa infection. J Aerosol Med Pulm Drug Deliv. 2017;30:29.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1291_CR14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21678707.2016.1196129","volume":"4","author":"A De Soyza","year":"2016","unstructured":"De Soyza A, Aksamit T. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Expert Opin Orphan Drugs. 2016;4:875\u201384.","journal-title":"Expert Opin Orphan Drugs"},{"key":"1291_CR15","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","volume":"45","author":"JD Chalmers","year":"2015","unstructured":"Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446\u201362.","journal-title":"Eur Respir J"},{"key":"1291_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1\u201323.","journal-title":"Eur Respir J"},{"key":"1291_CR17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","volume":"54","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2018","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, M\u00e1iz L, Olveira C, Gir\u00f3n RM, de la Rosa D, Blanco M, et al. Spanish guidelines on treatment of bronchiectasis in adults. Archivos de Bronconeumolog\u00eda (English Edition). 2018;54:88\u201398.","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"key":"1291_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2013.11.005","volume":"86","author":"S Claus","year":"2014","unstructured":"Claus S, Weiler C, Schiewe J, Friess W. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86:1\u20136.","journal-title":"Eur J Pharm Biopharm"},{"key":"1291_CR19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/17425240903110710","volume":"6","author":"D Traini","year":"2009","unstructured":"Traini D, Young PM. Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv. 2009;6:897\u2013905.","journal-title":"Expert Opin Drug Deliv"},{"key":"1291_CR20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","volume":"61","author":"SK Lai","year":"2009","unstructured":"Lai SK, Wang Y-Y, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009;61:86\u2013100.","journal-title":"Adv Drug Deliv Rev"},{"key":"1291_CR21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2014.05.008","volume":"75","author":"I d\u2019Angelo","year":"2014","unstructured":"d\u2019Angelo I, Conte C, La Rotonda MI, Miro A, Quaglia F, Ungaro F. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev. 2014;75:92\u2013111.","journal-title":"Adv Drug Deliv Rev"},{"key":"1291_CR22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2010.11.007","volume":"150","author":"E Wenk","year":"2011","unstructured":"Wenk E, Merkle HP, Meinel L. Silk fibroin as a vehicle for drug delivery applications. J Control Release. 2011;150:128\u201341.","journal-title":"J Control Release"},{"key":"1291_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2015.03.020","volume":"206","author":"F Mottaghitalab","year":"2015","unstructured":"Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H. Silk fibroin nanoparticle as a novel drug delivery system. J Control Release. 2015;206:161\u201376.","journal-title":"J Control Release"},{"key":"1291_CR24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1517\/17425247.2015.993314","volume":"12","author":"SY Kim","year":"2015","unstructured":"Kim SY, Wong AH, Abou Neel EA, Chrzanowski W, Chan HK. The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering. Expert Opin Drug Deliv. 2015;12:869\u201387.","journal-title":"Expert Opin Drug Deliv"},{"key":"1291_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/ab500101c","volume":"1","author":"I Schultz","year":"2015","unstructured":"Schultz I, Vollmers F, L\u00fchmann T, Rybak J-C, Wittmann R, Stank K, et al. Pulmonary insulin-like growth factor I delivery from trehalose and silk-fibroin microparticles. ACS Biomater Sci Eng. 2015;1:119\u201329.","journal-title":"ACS Biomater Sci Eng"},{"key":"1291_CR26","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/mp400030n","volume":"10","author":"HX Ong","year":"2013","unstructured":"Ong HX, Traini D, Salama R, Anderson SD, Daviskas E, Young PM. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. Mol Pharm. 2013;10:2915\u201324.","journal-title":"Mol Pharm"},{"key":"1291_CR27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/bit.23046","volume":"108","author":"Y Yang","year":"2011","unstructured":"Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y. Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng. 2011;108:1441\u20139.","journal-title":"Biotechnol Bioeng"},{"key":"1291_CR28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rmed.2016.06.007","volume":"117","author":"R Wilson","year":"2016","unstructured":"Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, et al. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respir Med. 2016;117:179\u201389.","journal-title":"Respir Med"},{"key":"1291_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jamp.2017.1415","volume":"31","author":"R Dhand","year":"2018","unstructured":"Dhand R. The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2018;31:121\u201338.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1291_CR30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jconrel.2005.12.009","volume":"111","author":"S Hofmann","year":"2006","unstructured":"Hofmann S, Wong Po Foo CT, Rossetti F, Textor M, Vunjak-Novakovic G, Kaplan DL, et al. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release. 2006;111:219\u201327.","journal-title":"J Control Release"},{"key":"1291_CR31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejpb.2005.02.002","volume":"60","author":"O Bayraktar","year":"2005","unstructured":"Bayraktar O, Malay \u00d6, \u00d6zgarip Y, Bat\u0131g\u00fcn A. Silk fibroin as a novel coating material for controlled release of theophylline. Eur J Pharm Biopharm. 2005;60:373\u201381.","journal-title":"Eur J Pharm Biopharm"},{"key":"1291_CR32","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1208\/s12249-018-1137-6","volume":"19","author":"M Razuc","year":"2018","unstructured":"Razuc M, Pi\u00f1a J, Ram\u00edrez-Rigo MV. Optimization of ciprofloxacin hydrochloride spray-dried microparticles for pulmonary delivery using design of experiments. AAPS PharmSciTech. 2018;19:3085\u201396. \nhttps:\/\/doi.org\/10.1208\/s12249-018-1137-6\n\n.","journal-title":"AAPS PharmSciTech"},{"key":"1291_CR33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","volume":"85","author":"J Weers","year":"2015","unstructured":"Weers J. Inhaled antimicrobial therapy\u2014barriers to effective treatment. Adv Drug Deliv Rev. 2015;85:24\u201343.","journal-title":"Adv Drug Deliv Rev"},{"key":"1291_CR34","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","volume":"18","author":"NYK Chew","year":"2001","unstructured":"Chew NYK, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res. 2001;18:1570\u20137.","journal-title":"Pharm Res"},{"key":"1291_CR35","first-page":"165","volume":"3","author":"S Sahoo","year":"2011","unstructured":"Sahoo S, Chakraborti CK, Mishra SC, Nanda UN, Naik S. FTIR and XRD investigations of some fluoroquinolones. Int J Pharm Pharm Sci. 2011;3:165\u201370.","journal-title":"Int J Pharm Pharm Sci"},{"key":"1291_CR36","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3109\/21691401.2015.1062389","volume":"44","author":"A Bhardwaj","year":"2016","unstructured":"Bhardwaj A, Mehta S, Yadav S, Singh SK, Grobler A, Goyal AK, et al. Pulmonary delivery of antitubercular drugs using spray-dried lipid-polymer hybrid nanoparticles. Artif Cell Nanomed B. 2016;44:1544\u201355.","journal-title":"Artif Cell Nanomed B"},{"key":"1291_CR37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.carbpol.2006.10.014","volume":"69","author":"Q Wang","year":"2007","unstructured":"Wang Q, Dong ZF, Du YM, Kennedy JF. Controlled release of ciprofloxacin hydrochloride from chitosan\/polyethylene glycol blend films. Carbohydr Polym. 2007;69:336\u201343.","journal-title":"Carbohydr Polym"},{"key":"1291_CR38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/(SICI)1097-0282(19980405)45:4<307::AID-BIP5>3.0.CO;2-P","volume":"45","author":"JP Anderson","year":"1998","unstructured":"Anderson JP. Morphology and crystal structure of a recombinant silk-like molecule, SLP4. Biopolymers. 1998;45:307\u201321.","journal-title":"Biopolymers"},{"key":"1291_CR39","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1016\/j.biomaterials.2010.02.024","volume":"31","author":"AS Lammel","year":"2010","unstructured":"Lammel AS, Hu X, Park SH, Kaplan DL, Scheibel TR. Controlling silk fibroin particle features for drug delivery. Biomaterials. 2010;31:4583\u201391.","journal-title":"Biomaterials"},{"key":"1291_CR40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/17425247.2011.568936","volume":"8","author":"EM Pritchard","year":"2011","unstructured":"Pritchard EM, Kaplan DL. Silk fibroin biomaterials for controlled release drug delivery. Expert Opin Drug Deliv. 2011;8:797\u2013811.","journal-title":"Expert Opin Drug Deliv"},{"key":"1291_CR41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11095-013-1132-2","volume":"31","author":"W Kaialy","year":"2014","unstructured":"Kaialy W, Hussain T, Alhalaweh A, Nokhodchi A. Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres. Pharm Res. 2014;31:60\u201376.","journal-title":"Pharm Res"},{"key":"1291_CR42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jconrel.2014.05.059","volume":"190","author":"T Yucel","year":"2014","unstructured":"Yucel T, Lovett ML, Keplan DL. Silk-based biomaterials for sustained drug delivery. J Control Release. 2014;190:381\u201397.","journal-title":"J Control Release"},{"key":"1291_CR43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jfoodeng.2008.10.020","volume":"94","author":"EHJ Kim","year":"2009","unstructured":"Kim EHJ, Chen XD, Pearce D. Surface composition of industrial spray-dried milk powders. 2. Effects of spray drying conditions on the surface composition. J Food Eng. 2009;94:169\u201381.","journal-title":"J Food Eng"},{"key":"1291_CR44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/aic.690410331","volume":"41","author":"G Meerdink","year":"1995","unstructured":"Meerdink G, Riet KVT. Modeling segregation of solute material during drying of liquid foods. AICHE J. 1995;41:732\u20136.","journal-title":"AICHE J"},{"key":"1291_CR45","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1016\/j.ces.2011.08.035","volume":"66","author":"XD Chen","year":"2011","unstructured":"Chen XD, Sidhu H, Nelson M. Theoretical probing of the phenomenon of the formation of the outermost surface layer of a multi-component particle, and the surface chemical composition after the rapid removal of water in spray drying. Chem Eng Sci. 2011;66:6375\u201384.","journal-title":"Chem Eng Sci"},{"key":"1291_CR46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17425247.2018.1450865","volume":"15","author":"ZY Zhao","year":"2018","unstructured":"Zhao ZY, Huang ZW, Zhang XJ, Huang Y, Cui YT, Ma C, et al. Low density, good flowability cyclodextrin-raffinose binary carrier for dry powder inhaler: anti-hygroscopicity and aerosolization performance enhancement. Expert Opin Drug Deliv. 2018;15:443\u201357.","journal-title":"Expert Opin Drug Deliv"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-019-1291-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T05:14:51Z","timestamp":1592975691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-019-1291-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1291-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"30 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"85"}}